European committee takes a second look at ... - Associated Press News
1 day ago · A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.. Biogen said Thursday that the drug, known in the U.S. as Leqembi, received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use as a treatment for early Alzheimer’s disease.
Biogen's stock rises after E.U. regulator reverses negative view of ...
1 day ago · Biogen Inc.'s stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai ...
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
2 days ago · Spinraza sales dropped $67 million to $381 million for the third quarter, which Biogen attributed to the loss of an annual tender in Russia. The drug has also suffered due to competition from Novartis’ gene therapy Zolgensma. Biogen is hoping that Spinraza can return to growth, potentially in combination with Zolgensma.
News - Biogen
Oct 30, 2024 · Biogen Reports Third Quarter 2024 Results. Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases. Biogen Appoints Daniel Quirk, MD, …
Biogen Bolsters Late-Stage Pipeline, Expands Immunology …
May 22, 2024 · Proposed acquisition builds on Biogen capabilities in immunology with plans to combine Human Immunology Biosciences expertise in immune-mediated indications with Biogen’s global development and commercial experience in rare diseases
Biogen to Realign Resources for Alzheimer's Disease Franchise
CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced plans to reprioritize its resources in Alzheimer’s disease (AD), a strategic therapeutic area expected to drive near and long-term growth.
Biogen discontinues Alzheimer’s medication Aduhelm - CNN
Jan 31, 2024 · The Alzheimer’s medication Aduhelm is being discontinued by drugmaker Biogen as it shifts resources to its other Alzheimer’s medication, Leqembi, and developing other treatments, the company...
Biogen in up to $1.8 bln deal as rare diseases take center stage
May 22 (Reuters) - Biogen (BIIB.O) said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its...
Biogen (BIIB) Raises Forecast as Alzheimer’s Drug Leqembi Shows …
Oct 30, 2024 · Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new...
Biogen Beats Estimates as Alzheimer’s Drug Gains Traction
Apr 24, 2024 · Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug Leqembi gained traction and cost cuts took hold.